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All previously characterized broadly neutralizing
antibodies to the HIV-1 envelope glycoprotein
(Env) target one of four major sites of vulnerability.
Here, we define and structurally characterize a
unique epitope on Env that is recognized by a
recently discovered family of human monoclonal an-
tibodies (PGT151–PGT158). The PGT151 epitope is
comprised of residues and glycans at the interface
of gp41 and gp120 within a single protomer and gly-
cans from both subunits of a second protomer and
represents a neutralizing epitope that is dependent
on both gp120 and gp41. Because PGT151 binds
only to properly formed, cleaved trimers, this
distinctive property, and its ability to stabilize Env
trimers, has enabled the successful purification of
mature, cleaved Env trimers from the cell surface
as a complex with PGT151. Here we compare the
structural and functional properties of membrane-
extracted Env trimers from several clades with those
of the soluble, cleaved SOSIP gp140 trimer.
INTRODUCTION
Over the past five years, many new broadly neutralizing anti-
bodies (bnAbs) that are able to neutralize diverse panels of
HIV-1 in vitro have been isolated from HIV-1-infected humans
(Burton et al., 2012b; Huang et al., 2012; Klein et al., 2013; Kwong
andMascola, 2012; Scheid et al., 2011;Walker et al., 2009, 2011;
Zhou et al., 2010). These advances have reinvigorated the pursuitof both active and passive HIV-1 vaccine strategies (Barouch
et al., 2013; Burton et al., 2012a; Horwitz et al., 2013; Klein
et al., 2012b; Shingai et al., 2013). The sole targets for bnAbs
are native, functional envelope glycoprotein (Env) trimers on the
virus surface. These trimers of gp120 and gp41 heterodimers
assemble after endoproteolytic cleavage of the gp160 precursor.
Immune selection pressures, combined with a high replication
rate and an error-prone reverse transcriptase, create hypervari-
able HIV-1 Env proteins. The trimer surface is also shielded by
an extensive array of glycans. Nonetheless, sites of vulnerability
on the virus do exist and four bnAb epitope clusters have been
characterized: a linear region of gp41 close to the viral membrane
(the membrane-proximal external region or MPER) (Huang et al.,
2012;Muster et al., 1993; Zwick et al., 2001), the CD4binding site
(CD4bs) on gp120 (Burton et al., 1994; Scheid et al., 2011; Wu
et al., 2011; Zhang et al., 2012; Zhou et al., 2010), an N332-
dependent epitope cluster on the glycosylated face of gp120
(Kong et al., 2013; Walker et al., 2011), and a site including the
N160 glycan on V2 at the trimer apex (Julien et al., 2013b;
McLellan et al., 2011; Walker et al., 2009, 2011). Another sus-
pected bnAb site on gp120 has also been partially characterized
(Klein et al., 2012a; Thali et al., 1993; Xiang et al., 2002; Zhang
et al., 2004). All known bnAbs characterized to date bind to one
of these sites, raising the question of whether all broadly neutral-
izing epitopes on Env have already been identified.
Analyzing human responses to viral infection by direct func-
tional screening (Simek et al., 2009; Walker et al., 2009, 2011)
has led to the isolation of several potent bnAbs, including a set
now designated as the PGT151 family (Falkowska et al., 2014,
this issue of Immunity). Here, we identify and structurally define
the complex quaternary epitope targeted by PGT151 family
members and show that it is present only on native-like, cleaved
forms of Env. The stability provided to native Env by PGT151
binding creates an opportunity to isolate and purify these trimersImmunity 40, 669–680, May 15, 2014 ª2014 Elsevier Inc. 669
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Figure 1. PGT151 and PGT152 Binding to SOSIP gp140 Env Trimer Is Dependent on Glycosylation and Cleavage and Requires the Prefusion
Conformation of gp41
(A) PGT151 binds strongly to BG505 SOSIP.664 gp140 trimers produced in untreated HEK293T cells but not to the same trimers produced in HEK293S cells
(Man5-9 glycans only) or in HEK293T cells treated with kifunensine (kif) (Man9 glycans only). PGT151 also does not bind BG505 gp120 monomers. 2G12, which
(legend continued on next page)
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Along with high-resolution X-ray crystal structures of the frag-
ment antigen binding (Fab) of PGT151 and PGT152, we present
single-particle electron microscopy (EM) reconstructions at
19–25 A˚ resolution of complexes of PGT151 Fab with cell
membrane-extracted Env from three different HIV-1 isolates
(clade A BG505, clade B JR-FL, and clade C IAVI C22) and
compare them with soluble, cleaved SOSIP.664 trimers (Julien
et al., 2013b, 2013c; Kong et al., 2013; Sanders et al., 2013). An-
alyses of the four PGT151-Env structures, in conjunction with
higher-resolution models of Env (Julien et al., 2013a; Lyumkis
et al., 2013) and mutagenesis data, reveal that PGT151 binds
an epitope that involves both inter- and intraprotomer contacts
with the trimer and is dependent on a subset of fully processed
glycans. We also show that PGT151 binds with a unique stoichi-
ometry of 2 Fabs per trimer that is probably linked to its quater-
nary preference. Thus, PGT151 binds an extensive epitope
spanning multiple protein subunits and enables high-fidelity
assessment and isolation of properly formed HIV-1 Env trimers
from membranes.
RESULTS
PGT151 Family bnAbs Bind Only Cleaved, Trimeric Env
and Require a Complex Glycan
In ELISA studies, PGT151 bound strongly to soluble, cleaved
BG505 SOSIP.664 trimers expressed in HEK293T cells (Fig-
ure 1A). These engineered trimers are stabilized by introduction
of a disulfide bond between position 501 in gp120 and position
605 in gp41 (termed SOS), along with an isoleucine to proline
substitution at position 559 (termed IP). The SOSIP trimers
have a native-like conformation and glycosylation profile that in-
cludes both high-mannose and more complex structures (Julien
et al., 2013b; Sanders et al., 2002, 2013). PGT151 does not bind
monomeric BG505 gp120 and reacts inefficiently with HEK293S
cell-expressed trimers that bear only high-mannose glycans
(Figure 1A). The latter observation is consistent with the prefer-
ence of PGT151 and PGT152 for tri- and tetra-antennary
N-linked glycans in a microarray study (Falkowska et al., 2014).
Here, we show that PGT151 and PGT152 react only weakly
(KDz 1mM) with tri-antennary N-linked glycans in an isothermal
titration calorimetry (ITC) solution-phase assay (Figure 1B).
The PGT151 family of bnAbs is highly specific for cleaved and
thus native-like trimers, whether soluble BG505 SOSIP.664 or
embedded in cell membrane (JR-FL) (Falkowska et al., 2014),
implying that cleavage causes rearrangements in Env quaternary
structure. To explore this property further, we first tested
PGT151 binding by ELISA to the His6-tagged BG505 IP.664binds high-mannose glycans, served as a control mAb. 2G12 binding to trime
increased as a result of the elevated amount of high-mannose glycans. The da
representative of at least two independent experiments.
(B) In an ITC assay, PGT151 and PGT152 Fabs bind with low affinity (KD z 1 m
integrated titration (bottom) curves are shown.
(C) PGT151 binds His-tagged BG505 SOSIP.664 and BG505 IP.664, but not to B
MAbs VRC01 and 2G12 to the BG505 IP.664 and BG505 WT.664 variants is grea
trimers because their epitopes on gp41 are occluded by the gp120 subunits, but
(middle). PGT151 binds the SOSIP.664 trimers and the IP.664 proteins, but does n
present only in the prefusion conformation of gp41. Data presented here were ch
duplicate and averaged values are shown.construct, which lacks the stabilizing disulfide bond between
gp120 and gp41 and, hence, is prone to gp120 dissociation,
leaving primarily gp41 immobilized in a trimeric prefusion confor-
mation on Ni-NTA ELISA plates (Ringe et al., 2013). Compared to
SOSIP.664, IP.664 exhibited much less VRC01 and 2G12 bind-
ing but increased binding of F240 and 7B2 (Figure 1C). These
nonneutralizing gp41 epitopes are exposed only when gp120
dissociates. PGT151 was still able to bind IP.664, albeit less effi-
ciently than to intact SOSIP.664 trimers. However, when the
I559P mutation, which stabilizes the prefusion trimeric confor-
mation of gp41 by impeding transition to the 6-helix bundle post-
fusion form (Caffrey et al., 1998; Sanders et al., 2002, 2004), was
also reversed in the WT.664 construct, PGT151 binding was
eliminated (Figure 1C). These findings suggest that PGT151
reactivity requires gp41 to be in a trimeric prefusion conforma-
tion and that gp120 contributes to the epitope.
Crystal Structures of PGT151 and PGT152 Fabs
To characterize the paratope of this class of bnAbs, we solved
crystal structures of PGT151 and PGT152 Fabs at resolutions
of 1.86 A˚ and 1.83 A˚, respectively (Table 1; Figures 2A and 2B).
Their overall structures are highly similar although we could not
compare the heavy-chain complementarity determining region
3 (HCDR3) because eight residues in the long PGT152 HCDR3
(26 residues) were disordered (Figure 2B). A long HCDR3 loop
is a feature common to most other glycan-binding bnAbs (Julien
et al., 2013c; Kong et al., 2013; McLellan et al., 2011; Pejchal
et al., 2011). Moreover, PGT151 and PGT152 have an unusually
long, 16 residue light-chain CDR1 (LCDR1); only 10% of human
light chain sequences in the Abysis database (http://www.bioinf.
org.uk/abysis/index.html) have an LCDR1 of 16 or more
residues.
PGT151 Stabilization Facilitates Purification of Stable,
Cleaved Cell-Surface-Expressed Env Trimers
To investigate the PGT151-trimer interaction, we developed a
method to extract fully cleaved trimers from the membrane of
transiently transfected HEK293F suspension cells via PGT151
IgG. The cleavage-competent Env constructs (JR-FL, BG505,
and IAVI C22) contain the gp41 transmembrane helices but
lack the cytoplasmic domain (CT) and are, therefore, referred
to as EnvDCT. PGT151 IgG-treated cells were lysed with
nonionic detergent and Env-PGT151 complexes were purified
on a Protein A column (Figures 2C and 2D). SDS and Blue
Native PAGE (BN-PAGE) showed that only cleaved, trimeric
Env was purified (Figure 2E and Figure S1A available online).
For all three isolates, only 10% of the total Env content (Fig-
ure 2F) could be purified in this way, suggesting that only ars produced in kifunensine-treated 293T cells or in 293S cells was modestly
ta were derived with a Ni-NTA ELISA and His-tagged Env proteins. Data are
M) to complex type asialo-tri-antennary glycans. The raw binding (top) and
G505 WT.664, as shown by Ni-NTA-capture ELISA. Binding of the anti-gp120
tly reduced (left). The anti-gp41 MAbs F240 and 7B2 do not bind to SOSIP.664
they do bind to IP.664 and WT.664 proteins from which gp120 has dissociated
ot bind cleaved WT.664 (right). These data suggest that the PGT151 epitope is
osen from two to six independent experiments. Each experiment was done in
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Table 1. Data Collection and Refinement Statistics for PGT151
and PGT152
PGT151-Fab PGT152Dgly-Fab
Data Collection
Space group C2 C2
Cell dimensions: a, b, c (A˚) 118.65, 66.98,
84.55
119.99, 66.30,
84.88
Cell dimensions: a, b, g () 90, 133.91, 90 90, 134.12, 90
Wavelength (A˚) 0.9795 1.0332
Resolution (A˚) 33.5–1.86
(1.89–1.86)
34–1.83 (1.86–1.83)
Observed reflections 132,470 (4,653) 311,320 (15,660)
Unique reflections 39,140 (1,501) 42,208 (2,088)
Completeness (%) 97.2 (74.5) 99.9 (100)
Redundancy 3.4 (3.1) 7.4 (7.5)
Rsym 0.08 (0.35) 0.08 (0.51)
I /sI 29.2 (4.6) 28.9 (8.3)
Refinement
Resolution (A˚) 34–1.86 33–1.83
No. reflections 39,127 42,203
Rcryst/Rfree
a 0.16/0.21 0.17/0.19
Protein atoms 3,530 3,454
Waters 485 511
Overall B value (A˚2) 27.6 27.9
Wilson B (A˚2) 19.3 22.8
Rmsd bond lengths (A˚) 0.006 0.007
Rmsd bond angles () 1.09 1.24
Ramachandran favored (%) 97.7 97.5
Ramachandran outliers (%) 0.0 0.0
Rotamer outliers (%) 0.7 0.5
PDB code 4NUG 4NUJ
Values in parentheses throughout are for highest-resolution shell.
a5% of reflections not used for refinement were used to calculate Rfree.
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form of cleaved, native trimers with PGT151-reactive glycans.
This proportion is probably larger than 10% on the cell sur-
face, because the method used to quantitate total Env content
includes extraneous intracellular, unprocessed Env that is
released from within the cell upon lysis.
We tested PG9, PGT128, and 2G12, but these bnAbs did not
enable Env trimers to be purified efficiently, or in large quantities,
from the cell membrane. The quaternary-specific bnAb PGT145
(Walker et al., 2011) did facilitate purification of some JR-FL
EnvDCT trimers, but the yield was lower. The PGT145-trimer
complexes were also substantially less stable than the corre-
sponding PGT151 complexes, which did not detectably disso-
ciate during multiweek storage at 4C (Figure 2G). To further
characterize the stabilizing effect of PGT151, we incubated the
JR-FL EnvDCT PGT151 and PGT145 complexes for 1 hr at
4C, 37C, 42C, or 65C and evaluated the degree of dissocia-
tion by BN-PAGE. The PGT145-trimer complex dissociated into
dimers and monomers at 42C, whereas the corresponding
PGT151 complex was stable at this temperature (Figure 2H).
Both complexes disintegrated completely at 65C (Figure 2H).672 Immunity 40, 669–680, May 15, 2014 ª2014 Elsevier Inc.Taken together, these data illustrate that quaternary-specific an-
tibodies, particularly PGT151, stabilize the highly labile Env
trimer structure.
Membrane-Extracted Env Trimers fromClades A, B, and
C Are Structurally Similar to Soluble SOSIP.664 Trimers
EM reconstructions of PGT151 Fabs in complex with EnvDCT tri-
mers from clades A (BG505), B (JR-FL), and C (IAVI C22) were
determined at resolutions of 22 A˚, 19 A˚, and 25 A˚, respec-
tively (Figures 4A–4C). All three reconstructions were highly
similar, with the following correlation coefficients between
maps: JR-FL: BG505 = 0.97, JR-FL: IAVI C22 = 0.96, and
BG505: IAVI C22 = 0.96. Whereas the EM reconstructions
were refined without imposing symmetry, the three-fold lobes
characteristic of the virion-associated Env trimer (Liu et al.,
2008) were readily apparent. Two dumbbell-shaped densities
indicative of Fabs emanated radially from the trimer. The Env
trimer in the EM reconstruction also resembled the unliganded
BaL Env tomogram (EMDB ID: 5019), which contained the full
gp120 and gp41 ectodomain as well as the transmembrane re-
gion (Figure 3E). For all three Env sequences, we did not observe
more than two PGT151 Fabs bound per trimer. This finding is
consistent with densitometric analysis of the SDS-PAGE of the
purified complexes and the substoichiometric binding between
the PGT151 Fab and the BG505 SOSIP.664 trimer in ITC and
SEC-MALS (Figures 3F, 3G, and S1B).
The EM reconstructions of membrane-derived BG505
EnvDCT complexes with PGT151 Fab allowed a direct compar-
ison with PGT151 complexes formed with recombinant, soluble,
cleaved BG505 SOSIP.664 gp140 trimers (Figure 3D). The two
reconstructions were highly similar overall (correlation coeffi-
cient of 0.96), as were the mode and orientation in which the
Fab interacts with these two versions of the BG505 trimer (Fig-
ures 3B and 3D). Thus, despite the engineered deletion of the
MPER and transmembrane regions and introduction of the
SOS and I559P trimer-stabilizing changes, the soluble BG505
SOSIP.664 trimers are structurally similar to cell membrane-
derived trimers at the moderate resolution obtained here; in
particular, both trimer forms contain the highly complex, quater-
nary, and glycan-dependent PGT151 epitope.
In contrast to JR-FL and BG505 EnvDCT, which both bound
two PGT151 Fabs, 60% of the IAVI C22 trimers bound
only one, as observed by EM. Of note is that PGT151 neutralizes
the IAVI C22 virus to a maximum extent of only 60%,
whereas JR-FL and BG505 viruses are both neutralized to
100% (Falkowska et al., 2014). These two observations may
be linked mechanistically, but understanding this relationship
will require further experiments. The BG505 SOSIP.664 trimers
also varied in their binding of PGT151. EM studies revealed
that approximately 50% of the trimers bound two Fabs while
the other 50% bound only one Fab, even when a 6-fold molar
excess of Fab was present (data not shown). The underlying
basis for this variation with SOSIP trimers remains to be deter-
mined but is perhaps rooted in some heterogeneity in glycan
composition in the SOSIP trimers, as previously postulated
(Lyumkis et al., 2013). Based on our collective observations,
PGT151 recognizes intact Env trimers across different clades
in a similar manner and binds with a stoichiometry of no greater
than two per trimer.
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Figure 2. Crystal Structures of PGT151 and PGT152 Fab andUse of PGT151 and PGT145 to Purify andCharacterize JR-FL andBG505 EnvDCT
Trimers from Cell Membranes
(A) Variable domain from the crystal structure of PGT151 Fab. The HCDR loops 1–3 are labeled and colored blue, red, and magenta, respectively, and the LCDR
loops 1–3 are labeled and colored green, yellow, and cyan, respectively. The long 26-residue CDR3 towers above the combining site.
(B) Superposition of crystal structures of PGT151 Fab (cyan) and PGT152 Fab (orange). See also Table 1 for data statistics.
(C) Scheme for purification of JR-FL EnvDCT from membranes via PGT151.
(D) SEC profile of the purified JR-FL EnvDCT: PGT151 complex; fractions containing the Fab-trimer complex are labeled in blue.
(E) SDS-PAGE (reducing and nonreducing) and BN-PAGE analysis of the purified JR-FL EnvDCT: PGT151 complex.
(F) Immunoblot analysis of cell surface expressed BG505 EnvDCT and JR-FL EnvDCT trimers, after incubation with PGT151, cell lysis, and fractionation on a
reducing SDS-PAGE. gp120 was detected on an immunoblot to assess the amount of Env captured by PGT151. The cell lysate and protein A flow through (FT)
fractions are compared (from step 3 in the purification scheme in C). Band intensities were analyzed by densitometry in the panels below the gel lanes (absolute
(legend continued on next page)
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Quaternary Epitope at the gp41-gp120 InterfacePGT151 Binds a Quaternary Inter- and Intraprotomer
Epitope on SOSIP Trimer
From analysis of the EM structure, we designed and screened
several BG505 SOSIP.664 trimer variants containing single and
double amino acid substitutions for PGT151 Fab binding by
ELISA. Residues from gp120 and gp41 both influence binding
to, and formation of, the PGT151 epitope, including several in
the gp120 C5 region (K490, T499, R500, R503) and gp41
(K601, N607, N611, N637) (Figure 4, residues listed conform to
HXB2 numbering). However, mutation of T499, R500, and
K601 residues had no effect on PGT151 neutralization on the
JR-CSF strain (R503S renders the virus inactive and K490 and
N607 mutants were not tested), whereas mutation of T499 and
neighboring residues did have a weak effect on neutralization
in the context of the LAI strain (Falkowska et al., 2014), indicating
that these gp120 residues might influence the PGT151 epitope
indirectly and/or only in certain Env subtypes. The N611Q and
N637Q substitutions (glycosylation sites in wild-type) in gp41 re-
sulted in significantly reduced PGT151 binding to BG505 SO-
SIP.664 trimers, and the double substitution led to a complete
loss of PGT151 binding (Figure 4B). The corresponding muta-
tions in the JR-CSF virus also markedly reduced PGT151
neutralization (Falkowska et al., 2014). Hence, these canonical
N-linked glycosylation sites, believed to harbor complex glycans
(Go et al., 2009), probably comprise part of the PGT151 epitope.
The subtle effects (and isolate differences) in both the neutraliza-
tion (Falkowska et al., 2014) and ELISA assays highlight the
difficulty in characterizing complex epitopes. The glycan promis-
cuity, as seen previously in PGT135, PGT121, and PGT128 bind-
ing, introduces further complexity in defining a single epitope
(Kong et al., 2013; D. Sok and D.R.B., unpublished data). The
direct visualization with the structural data is extremely valuable
to define the location, nature, and extent of the PGT151 epitope.
The exact extent of this epitope might be slightly different be-
tween isolates because PGT151 can accommodate some vari-
ability and single-point mutations (Falkowska et al., 2014).
Fitting the crystal structure of the PGT151 Fab and the EM
and X-ray structures of the BG505 SOSIP.664 trimers (Lyumkis
et al., 2013; PDB ID: 3J5M; Julien et al., 2013a; PDB ID: 4NCO)
into the reconstruction of the JR-FL EnvDCT: PGT151 Fab com-
plex showed that the epitope involves regions of both gp120 and
gp41 (Figure 5A). This conclusion is consistent with the absolute
requirement for a fully native trimer conformation (Falkowska
et al., 2014). The correct orientation of the Fab in the reconstruc-
tion was determined using cytochrome B562RIL (BRIL) engi-
neered into the antibody LC that added extra density to one
side of the Fab (Figure S2). In this orientation, the light chain
CDR loops are in close proximity to and possibly interact with
gp120 glycans N262 and N448 from one protomer, whereas
the light chain framework region 3 (LFR3) might contact N276
from the adjacent protomer (Figure 5B). The LCDR1 is in closeintensities, black numbers; relative percentages, blue numbers). Overall,10%of
A as a PGT151-trimer complex, and the remaining 90% was in the FT fractions
(G) Blue native PAGE analysis showing the relative stability of JR-FL EnvDCT or
cubation at 4C. From left to right: JR-FL EnvDCT: PGT151 is stable for 40 days (40
(7d) and is fully dissociated after 40 days (40d); and BG505 EnvDCT: PGT151 is st
(H) BN-PAGE assessment of the stability of JR-FL EnvDCT in complex with either
(left and middle). In a densitometric analysis, the intensities of the trimer bands a
674 Immunity 40, 669–680, May 15, 2014 ª2014 Elsevier Inc.proximity to the C1 region of one gp120 protomer and might
contribute weakly to antibody affinity (Figure 5C). The long
HCDR3 reaches into the interprotomer cavity at the interface be-
tweengp120 andgp41 (Figures 5Dand5E). In the high-resolution
SOSIP.664 X-ray andEMstructures (Julien et al., 2013a; Lyumkis
et al., 2013), this region contains additional unmodeled density
that probably corresponds to the fusion peptide-proximal region
of HR1 and the fusion peptide. Additionally, the back face of the
HCDR loops contacts the adjacent gp41, in a region of HR2 con-
taining glycans at N637 and potentially N611 (Figure 5D). Overall,
these data illustrate that PGT151 binds a complex quaternary
epitope that involves the gp120-gp41 interface of one protomer
andoneormoreglycans that areattached to thegp41HR2 region
of the adjacent protomer. This epitope does not overlap with any
previously identified bnAb epitopes on the Env trimer (Figure 6).
DISCUSSION
Theweak, noncovalent associationbetweengp41andgp120has
madestructural studiesof either solubleor full-lengthcleavedEnv
trimers extremely challenging. Furthermore, uncleaved forms of
Envarehighlyprone toadoptingnonnative conformations, partic-
ularly when expressed as soluble proteins but also when present
on the cell surface (Pancera andWyatt, 2005; Ringe et al., 2013).
In the context of the BG505 genotype, SOSIP mutations enable
the production of soluble, cleaved trimers that are close antigenic
(Sanders et al., 2013) and structural (Julien et al., 2013a; Khayat
et al., 2013; Lyumkis et al., 2013) mimics of native Env. Here,
we show that the PGT151 bnAb not only selectively recognizes
cleavedSOSIP trimers, but also stabilizesprefusionnativeEnv tri-
mers extracted from the cell surface, thereby preventing dissoci-
ation of gp120 from gp41. Thus, it appears that the engineered
SOS disulfide bond between gp120 and gp41 and binding of
PGT151 to an epitope proximal to that region are different ways
to stabilize the gp120-gp41 interaction within trimers. Accord-
ingly, this property of PGT151 creates a new and highly specific
method for extracting native trimers for multiple subtypes
(roughly 60% of Env sequences, based on the neutralization
breadth; Falkowska et al., 2014) from the membranes of Env-ex-
pressingcells; thenonnative, andprobablymoreabundant, forms
of trimer that are also present on the membranes are not recog-
nized by PGT151 and, hence, are eliminated during the purifica-
tion process. The broadly neutralizing epitope that we describe
here also has implications on the mode and mechanism of
neutralization by PGT151. Because CD4 is still able to bind the
Env-PGT151 complex, PGT151 probably neutralizes the virus
by stabilizing the gp41 prefusion conformation and the gp120-
gp41 interaction, thus precluding CD4- and/or coreceptor-
induced conformational changes required for membrane fusion.
Overall, the PGT151 epitope is quite complex and requires
gp160 cleavage, a properly formed quaternary gp120-gp41the total gp120 detected (cell surface and intracellular) was captured on protein
and, hence, nonreactive to PGT151.
BG505 EnvDCT complexes with either PGT151 Fab or PGT145 Fab after in-
d) with no dissociation; JR-FL EnvDCT: PGT145 partly dissociates after 7 days
able for 30 days (30d), whereas BG505 EnvDCT: PGT145 is partly dissociated.
PGT151 Fab or PGT145 Fab after incubation at different temperatures for 1 hr
re normalized against the total Env protein content of each lane (right).
Figure 3. Membrane-Derived, PGT151-Purified Env Trimers from Clades A, B, and C All Share Similar Structural Features with Soluble,
Cleaved SOSIP Trimers and Are Bound by PGT151 in a Substoichiometric Manner
(A–C) Top (left) and side (right) views of three different EnvDCT: PGT151 Fab EM reconstructions, showing two Fabs bound per trimer. The Env trimers are (A)
BG505 (clade A), (B) JR-FL (clade B), and (C) IAVI C22 (clade C).
(D) For comparison, top and side views are shown for the BG505 SOSIP.664: PGT151 Fab complex reconstruction.
(E) Comparison of the PGT151-liganded JR-FL EnvDCT trimer reconstruction (pink; same as B) with the cryo-electron tomographic reconstruction of the
unliganded BaL-1 virion-associated Env spike (EMDB ID: 5019) on the viral surface (gray). See also Figure S4 and Table S1.
(F) ITC analysis of high-affinity PGT151 binding to BG505 SOSIP.664 trimers. The affinity and stoichiometry (N) were calculated from an average of two ex-
periments. The N = 1.3 value is higher than the previously reported stoichiometry of N = 0.6–0.8 for one PG9 binding to the BG505 SOSIP.664 trimer (Julien et al.,
2013b) and lower than the N = 2.3–2.4 for PGT121, PGT128, and 2G12 binding to the same trimer (Sanders et al., 2013). The inference is that2 PGT151 Fabs are
bound per trimer. Data analysis was carried out bymeans of a single-site bindingmodel. The ITC data do not fit a 2-sitemodel, which argues against a cooperative
binding modality. The KD was determined as an average from three measurements. Binding affinity was further assessed by bio-layer interferometry in com-
parison with two other bnAbs (Figure S1C).
(G) Densitometric analysis of a reducing SDS-PAGE of JR-FL EnvDCT trimers purified from cell membranes via either PGT151, PGT128, or PGT145. The black
numbers denote the respective peak intensities. The blue numbers in brackets indicate the relative intensity of the respective peak compared to the corre-
sponding peak on the PGT151 panel. Although the intensities of the gp120 bands are comparable (0.94–1.0) in each case, the relative intensities of the Fab bands
are 0.6 and 1.5 for the PGT145 and PGT128 purifications, respectively, indicating that the PGT151 stoichiometry lies between PGT145 (which binds with a
stoichiometry of 1 per trimer; McLellan et al., 2011; Sanders et al., 2013; Walker et al., 2011) and PGT128 (which binds with a stoichiometry of 3 per trimer; Pejchal
et al., 2011). Note that PGT128 allowed for extraction of only a very small amount of Env, whichwas only sufficient for SDS-PAGE. Neither the yield nor the purity of
the sample was in the range of that achieved with PGT151 or PGT145.
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Figure 4. The PGT151 Epitope on BG505 SOSIP.664 Trimer Consists of Residues from gp141 and gp120
(A) PGT151 binding, assessed by Ni-NTA ELISA, is reduced when His6-tagged BG505 SOSIP.664 variants contain certain substitutions in the C5 region of gp120.
In the control, 2G12 binding is only mildly affected by the same substitutions.
(B) PGT151 binding, assessed by ELISA, is reduced when BG505 SOSIP.664 variants contain certain substitutions in gp41. Point substitutions of N611 and N637
that eliminate glycan sites are shown in the lower panel. For comparison, most substitutions had no effect on 2G12 binding, although the K601A and N607K
changes did cause a modest reduction. Assays were done with His- or D7324-tagged BG505 SOSIP proteins (as indicated in the figure).
(C) Summary of substitutions in BG505 SOSIP.664 trimers that affect PGT151 binding. Binding ability is scored on a scale from no binding () to strong binding
(++++). The analysis is derived from mean values of 3–5 experiments for each of the variants. Color code is as follows: red, weak to no binding; yellow/orange,
moderate binding; green, strong binding. Trimerization and cleavagewere comparable toWTSOSIP as assessed by SDS-PAGE and BN-PAGE (data not shown).
We cannot exclude the possibility that mutations proximal to the SOS disulfide bond (residues 501 and 605) change the local stability of the trimer and, therefore,
binding by PGT151. Both direct and indirect effects are consistent with PGT151 interactions at the gp120-gp41 interface.
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forms). Accordingly, PGT151 reactivity may represent one of
the best ways to identify and evaluate native, functional Env
trimers. No known bnAb has such a complex reactivity profile,
although various antibodies with trimer preference (PG9)
(Julien et al., 2013b; Walker et al., 2009), cleavage preference
(VRC06) (Li et al., 2012), and the possible involvement of
both gp120 and gp41 moieties (M43) (Zhang et al., 2012)
have been reported.
It was not possible under any conditions that we tried to
generate an Env trimer complex with three Fabs bound. A
detailed mechanistic explanation for binding of less than three
Fabs per trimer remains to be determined, but we postulate
that binding of the first and second Fabs may induce subtle allo-
steric effects on the Env structure through interprotomer interac-
tions, rendering the third epitope of the trimer unavailable or not
properly configured for PGT151 binding.
The Env-PGT151 complex may also be useful for antigenicity
and immunogenicity studies because PGT151 does not block676 Immunity 40, 669–680, May 15, 2014 ª2014 Elsevier Inc.the CD4 binding site, the N332 supersite of vulnerability, or the
N160 antigenic site (Falkowska et al., 2014), on at least one, if
not all, protomers. Similarly, because passive administration of
bnAbs can suppress infection and lower viral titers to undetect-
able levels for the duration of treatment, members of the PGT151
family may also be useful constituents of bnAb combinations
that are being considered for antiviral therapy, in view of the non-
overlap between this epitope and others (Balazs et al., 2012;
Barouch et al., 2013; Horwitz et al., 2013; Klein et al., 2012b).
Thus, this described fifth site of vulnerability expands our under-
standing of the antigenic surface of Env and offers another
opportunity for combating HIV-1.EXPERIMENTAL PROCEDURES
Expression and Purification of PGT151, PGT152, PGT145, and
PGT128 Antibodies
IgG and Fab fragments of all antibodies were expressed in HEK293F suspen-
sion cells as previously described (Pejchal et al., 2011).
Figure 5. Modeling of the PGT151 Epitope in
the Context of the High-Resolution EM
Structure of the Soluble, Cleaved BG505 SO-
SIP.664 Trimer
(A) Top and side view of the reconstruction of the
JR-FL EnvDCT: PGT151 Fab complex, fitted with
the atomic-level EM model of the BG505 SO-
SIP.664 trimer (PDB ID: 3J5M) (Lyumkis et al.,
2013). The gp120 protomers are in gray and the
gp41 HR1 and HR2 helices in purple. On the two
copies of PGT151 Fab, the heavy chain (HC) is in
dark blue and the light chain (LC) in light blue.
(B) Top view as in (A). The PGT151 LC is predicted
to interact with glycans from two gp120 protomers
(labeled gp120 A and B) and amino acid residues
from one gp120 protomer. The putative interacting
glycans are depicted as spheres in shades of yel-
low, and the glycosylation site position (Asn) is
shown in orange. LCDR coloring is shown as in
Figure 2A.
(C) The same view as in (B), showing regions of C1
that could potentially interact with LCDR1. In light
pink are residues 56–63, and dark pink 75–82.
(D) In a side view as in (A), putative PGT151 HC
interactions with one gp120 protomer (gray) and
two gp41 protomers (purple) are shown. The map
shows a single gp120 and the gp41 trimer,
segmented from the high-resolution EM structure
3J5M. The HR helices of gp41 B are depicted as
purple ribbons. HCDR3 appears to interact with
gp140 protomer A at the gp41-gp120 interface,
near the fusion peptide proximal region (FPPR)
shown in brown. The N637 glycosylation site from
protomer B shown in orange is in close proximity to
the PGT151 HC.
(E) The glycan at residue N637 is modeled as a
tetra-antennary GalNac complex glycan that was
shown to interact with all members of the PGT151 family (Falkowska et al., 2014). The EM density in cyan, not modeled in the high-resolution structures, is
predicted to encompass the putative location of the HR2 residues 611–624 as depicted by the dotted line. The orange circle and arrow, respectively, indicate the
putative position and orientation of N611 and its glycan based on the neutralization assay. See also Figure S2 and Movie S1.
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Crystallization trials with PGT151 and PGT152 Fab were set up with the IAVI/
Joint Center for Structural Genomics (JCSG)/TSRI CrystalMation robotic sys-
tem (Rigaku), at a concentration of 13 mg/ml in 50 mM Tris-Cl, 150 mM NaCl
(pH 7.5). Initial crystals of the PGT151 Fab fragment were obtained in 40%PEG
600, 0.1 M phosphate-citrate (pH 4.2). To improve crystallization of PGT152
Fab, a glycan was removed by a light-chain N107K mutation (PGT152DGlyc).
Crystals for PGT151 and PGT152 Fabs were optimized by microseeding,
which improved crystal formation under several conditions in an optimized
screen developed at the JCSG (M. Deller and I.A.W., unpublished data).
Data were collected at APS 23ID-B and at CLS 08ID-1.
Structure Determination and Refinement
Structures were solved by PHASER (McCoy, 2007) with an unrelated Fab
(PDB: 2FX7) as a search model for PGT151 Fab. For the PGT152DGlyc Fab,
the PGT151 Fab structure was used as search model. Data reduction and
scaling was performed with HKL-2000 (Otwinowski and Minor, 1997). COOT
(Emsley and Cowtan, 2004) and PHENIX (Adams et al., 2010) were used for
model building and refinement. Data collection and refinement statistics are
reported in Table 1.
Expression and Purification of JR-FL EnvDCT, BG505 EnvDCT, and
IAVI C22 EnvDCT Proteins
HEK293F suspension cells were transfected with a pSVIIIenv plasmid ex-
pressing either JR-FL EnvDCT E168K (referred to here as JR-FL EnvDCT,
because the E168K mutation is required for the PG9 epitope but does not
affect PGT151 binding) or IAVI C22 EnvDCT. Alternatively, cells were trans-fected with a phCMVIII plasmid containing a codon-optimized sequence for
either BG505-EnvDCT or JR-FL-EnvDCT under the control of a CMV promoter.
In all cases, the cells were cotransfected with a plasmid expressing the Tat
transactivator protein to enhance Env expression. For BG505 EnvDCT and
IAVI C22 EnvDCT expression, the cells were additionally cotransfected with
pcDNA3.1 Furin to enhance gp160 cleavage. The cells were harvested after
40 hr, washed, and resuspended in PBS before incubation with 100 mg/ml of
PGT151 IgG (1 hr, 4C). The cells were then washed to remove excess IgG
and resuspended in lysis buffer (PBS, 0.5% Triton X-100, protease inhibitors
[Roche]) before cell debris was removed by centrifugation (30,000 3 g,
30 min). The supernatant was loaded onto a Protein A column, followed by
extensive washing and subsequent on-column IgG cleavage with Ficin
(20 mg/ml) in 50 mM Tris (pH 7.0), 2 mM EDTA, 150 mM NaCl, 0.1% DDM for
4 hr at RT. The Env-PGT151Fab complex was then eluted by gravity flow
and analyzed by SEC. The same procedure was used for purification of Env-
PGT145 and Env-PGT128 complexes.
Expression and Purification of BG505 SOSIP.664
The BG505 SOSIP.664 construct as well as expression and purification were
exactly as described previously (Julien et al., 2013a; Lyumkis et al., 2013;
Ringe et al., 2013; Sanders et al., 2013). BG505 IP.664 does not carry the
SOS gp120-gp41ECTO disulfide bond, and BG505 WT.664 additionally lacks
the I559P mutation (used in Figure 1C).
Ni-NTA-Capture and D7324-Capture ELISAs for BG505 Env Proteins
SOSIP trimer ELISAs were performed as described previously (Sanders et al.,
2013) by using raw supernatants from cells transiently expressing BG505Immunity 40, 669–680, May 15, 2014 ª2014 Elsevier Inc. 677
Figure 6. PGT151 Binds to a New Site of Vulnerability that Does Not
Overlap with Any Other bnAb Epitopes
The JR-FL EnvDCT: PGT151 Fab reconstruction of the new PGT151 epitope
compared with the docking of representative Fabs that recognize three of the
four previously known bNAb epitope clusters (V1/V2 plus N160 glycan, N332
glycan, CD4bs). We cannot exclude the possibility that access to the CD4bs
might be blocked partly by the two bound PGT151 Fabs; accordingly, PGV04
binding to the CD4bs is shown on the third protomer interface that does
not have PGT151 bound. The PGT151 binding site on the open face is also
shown in blue for reference, with the PGT151 Fab density removed for clarity
(right panel). A similar analysis of BG505 SOSIP.664 trimers produces nearly
identical results. See also Figures S3 and S4.
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Quaternary Epitope at the gp41-gp120 InterfaceSOSIP.664-His- or D7324-tagged BG505 Env proteins, except for Figure 1A,
where purified Env trimers were used. The percentage of all Env proteins pre-
sent in trimeric form was always >60% in the supernatants used for ELISA
assays.
Isothermal Titration Calorimetry
MicroCal iTC200 and Auto-iTC200 instruments (GE Healthcare) were used to
perform isothermal titration calorimetry (ITC) measurements as described pre-
viously (Julien et al., 2013b). For the PGT151:BG505 SOSIP.664 titration
experiment, the Env trimer was deposited in the cell at concentrations be-
tween 4.4 and 4.7 mM, and the Fab was in the pipette at concentrations be-
tween 79 and 102 mM. In the glycan: PGT151 titration experiments, PGT151
Fab was added to the cell at 100 mM with glycans in the pipette at 4–5 mM
(for synthesis of glycans, see Supplemental Experimental Procedures). Data
analysis was carried out with Origin 7.0 software via a single-site binding
model.
Electron Microscopy and Sample Preparation
Grids for single-particle EM were prepared as described previously (Kong
et al., 2013). Data for the JR-FL EnvDCT: PGT151 complex were collected
with an FEI Tecnai F20 electron microscope operating at 120 keV coupled
with a Gatan US4000 4k3 4k CCD camera at a magnification of 100,0003 re-
sulting in a pixel size of 1.09 A˚ at the specimen plane. All other complexes were
imaged on an FEI Tecnai T12 electron microscope operating at 120 keV
coupled with a Tietz TemCam-F416 4k 3 4k CMOS camera via automated
data collection via the LEGINON interface. The imaging magnification was
52,0003 with in a pixel size of 2.05 A˚ at the specimen plane. All data were
collected as described previously (Kong et al., 2013) with an electron dose
of 25–28 e/A˚2. For the random conical tilt (RCT) method with JR-FL EnvDCT:
PGT151, the sample was prepared as before with a carbon-coated C-Flat 400
mesh grid. The data were collected with the Leginon RCT data collection inter-
face (Yoshioka et al., 2007) on a Tecnai F20 electron microscope at 120 keV,
with the tilt pairs at 0 and 50, with a nominal defocus of 1 mm. Micrographs
were collected on a Gatan 4k 3 4k camera at a magnification of 62,0003 and
pixel size of 1.75 A˚.
Image Processing
Particle picking and classification was carried out as described previously
(Julien et al., 2013b). Template-based particle picking was carried out on the
60 RCT tilt pairs via seven representative classes from the single-particle refer-
ence-free class averages. Pickswere automatically alignedviaAppion and then
assessedmanually, yielding3,152particle tilt pairs,whichwere subject to refer-
ence-free 2D classification via XmippMaximumLikelihood Alignment (Scheres678 Immunity 40, 669–680, May 15, 2014 ª2014 Elsevier Inc.et al., 2005a, 2005b). Five RCT models were generated from these data, each
resulting fromapproximately 200particle tilt pairs. Twoof themodelsgenerated
that hadwell-defined trimer and Fab densities were used as the initial model for
projection matching refinement with a template stack of 60 images for 90 iter-
ations. The resulting two models were further refined with a bin 4 substack of
5,798 particles from the single-particle data set for 29 iterations, after which
the twomodelswere nearly identical (Figure S4). Additional datawere collected
for the single-particle analysis and sorted as stated above.One of thesemodels
was selected as the initial model for the final raw particle refinement. Models
other than the JR-FL EnvDCT: PGT151 trimer were refined from independently
generated by common lines in the EMAN2 package via reference-free 2D class
averages (Tang et al., 2007). No symmetry was applied to any of the projection-
matching refinements,whichwere carriedoutwith theEMANsoftwarepackage
(Ludtke et al., 1999). Refinement parameters and final resolution for each EM
reconstruction are summarized in Table S1.
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(PGT152Dgly-Fab). The EM reconstructions are deposited in the Electron
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